Dyne Therapeutics Prepares for Investor Update
WALTHAM, Mass. – Dyne Therapeutics, Inc. (Nasdaq: DYN) is setting the stage for an important forthcoming event that aims to inform stakeholders about significant advancements in the treatment for myotonic dystrophy type 1 (DM1). The investor conference call and accompanying webcast will occur tomorrow at 8:00 a.m. ET. The company has committed to issuing a detailed press release ahead of this informative session, ensuring that investors are fully updated.
Live Webcast Available
This live session will feature a comprehensive discussion of DYNE-101, a promising therapeutic being developed for those affected by DM1. The webcast can be conveniently accessed through the Investors & Media section on Dyne’s official website. In addition to live participation, a replay will be available for 90 days after the live presentation. Accompanying slides will also be shared to enhance investor understanding.
Accessing the Event
To attend the live webcast or view the recordings later, investors are encouraged to visit the dedicated Events & Presentations page on Dyne Therapeutics’ website. This transparency highlights the company's commitment to maintaining open communication with its investor community.
About Dyne Therapeutics and Its Mission
Dyne Therapeutics stands at the forefront of innovation in the realm of therapeutics for genetically driven neuromuscular diseases. Utilizing its cutting-edge FORCE™ platform, the company is focused on developing therapies that not only target muscle tissues but also effectively engage with the central nervous system (CNS). This groundbreaking approach aims to address the significant challenges in drug delivery for these complex conditions.
Pioneering Development in Neuromuscular Diseases
The company boasts an extensive pipeline, actively progressing clinical programs for conditions such as myotonic dystrophy type 1 and Duchenne muscular dystrophy (DMD). Additionally, Dyne is exploring preclinical programs aimed at facioscapulohumeral muscular dystrophy (FSHD), showcasing a robust strategy to tackle various neuromuscular disorders.
Investor Relations and Media Contacts
For investors wanting to delve deeper into Dyne's findings or seek clarification on specific aspects of the company’s strategies, the following contacts are available:
Investors
Mia Tobias
Email: ir@dyne-tx.com
Phone: 781-317-0353
Media
Stacy Nartker
Email: snartker@dyne-tx.com
Phone: 781-317-1938
Frequently Asked Questions
What is the purpose of the investor conference call?
The call aims to provide updates on Dyne Therapeutics' clinical advancements, specifically regarding DYNE-101 for myotonic dystrophy type 1.
When is the conference call scheduled?
The investor conference call is scheduled for tomorrow at 8:00 a.m. ET.
How can I access the live webcast?
The live webcast can be accessed through the Events & Presentations page on Dyne Therapeutics' website.
Is there a replay available after the live event?
Yes, a replay of the webcast will be accessible for 90 days following the event.
What other diseases is Dyne Therapeutics targeting?
In addition to myotonic dystrophy type 1, Dyne is also advancing therapies for Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy.